GLAND

GLAND PHARMA

Large Cap BSE: 543245 NSE: GLAND
₹2364.9
16.8 (0.72%)
As on 13 August, 2022 | 03:36

Gland Pharma Share Price

Gland Pharma Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Gland Pharma Share Returns

  • Over 1 Month -4.88%
  • Over 3 Month -17.07%
  • Over 6 Month -33.25%
  • Over 1 Year -45.21%

Gland Pharma Key Statistics

P/E Ratio 35.7
PEG Ratio 6.6
Market Cap Cr 38,940
Price to Book Ratio 5.4
EPS 73.4
Dividend 0
Relative Strength Index 48.1
Money Flow Index 62.54
MACD Signal -81.35
Average True Range 73.08

Gland Pharma Investment Rating

  • Master Rating:
  • Gland Pharma has an operating revenue of Rs. 4,103.71 Cr. on a trailing 12-month basis. An annual revenue growth of 29% is outstanding, Pre-tax margin of 37% is great, ROE of 16% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 4 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Gland Pharma Financials
  • Indicator
  • Jun 2022
  • Mar 2022
  • Dec 2021
  • Sep 2021
  • Jun 2021
  • Mar 2021
  • Oper Rev Qtr Cr
  • 857
  • 1,103
  • 1,063
  • 1,080
  • 1,154
  • 888
  • Operating Expenses Qtr Cr
  • 587
  • 755
  • 714
  • 704
  • 718
  • 560
  • Operating Profit Qtr Cr
  • 270
  • 348
  • 349
  • 377
  • 436
  • 328
  • Depreciation Qtr Cr
  • 35
  • 31
  • 28
  • 26
  • 25
  • 25
  • Interest Qtr Cr
  • 1
  • 2
  • 1
  • 1
  • 1
  • 1
  • Tax Qtr Cr
  • 79
  • 95
  • 93
  • 99
  • 121
  • 89
  • Net Profit Qtr Cr
  • 229
  • 286
  • 273
  • 302
  • 351
  • 260

Gland Pharma Technicals

EMA & SMA

Current Price
2364.9
16.8 (0.72%)
  • Bullish Moving Average
  • ___
  • 7
  • Bearish Moving Average
  • ___
  • 9
  • 20 Day
  • 2346.43
  • 50 Day
  • 2511.32
  • 100 Day
  • 2756
  • 200 Day
  • 3185.64
  • 20 Day
  • 2318.53
  • 50 Day
  • 2511.72
  • 100 Day
  • 2822.54
  • 200 Day
  • 3187.08

Gland Pharma Resistance and Support

PIVOT
₹2334.
Resistance
  • First Resistance
  • 2365.25
  • Second Resistance
  • 2382.4
  • Third Resistance
  • 2413.65
Support
  • First Resistance
  • 2316.85
  • Second Resistance
  • 2285.6
  • Third Resistance
  • 2268.45
  • RSI
  • 48.1
  • MFI
  • 62.54
  • MACD Single Line
  • -81.34
  • MACD
  • -56.99

Gland Pharma Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • 147,869
  • 7,325,430
  • 49.54
  • Week
  • 212,372
  • 14,464,674
  • 68.11
  • 1 Month
  • 666,229
  • 39,487,365
  • 59.27
  • 6 Month
  • 363,198
  • 25,060,695
  • 69

Gland Pharma Result Highlights

Gland Pharma Synopsis

NSE-Medical-Generic Drugs

Gland Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 4400.71 Cr. and Equity Capital is Rs. 16.43 Cr. for the Year ended 31/03/2022. Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276.
  • Market Cap
  • 38,939
  • Sales
  • 4,104
  • Shares in Float
  • 6.92
  • No of funds
  • 225
  • Yield
  • Book Value
  • 5.43
  • U/D Vol ratio
  • 0.6
  • LTDebt / Equity
  • Alpha
  • -0.24
  • Beta
  • 0.52

Gland Pharma

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 57.87%
  • 58%
  • 58%
  • Mutual Funds
  • 15.54%
  • 11.22%
  • 10.55%
  • Insurance Companies
  • 1.17%
  • 0.72%
  • 0.65%
  • Foreign Portfolio Investors
  • 9.41%
  • 10.72%
  • 11.3%
  • Financial Institutions/ Banks
  • 0.01%
  • Individual Investors
  • 3.71%
  • 3.69%
  • 3.58%
  • Others
  • 12.3%
  • 15.65%
  • 15.91%

Gland Pharma Management

  • Name
  • Designation
  • Mr. Yiu Kwan Stanley Lau
  • Chairman & Ind.Director
  • Mr. Srinivas Sadu
  • Managing Director & CEO
  • Mr. Qiyu Chen
  • Non Executive Director
  • Mr. Yifang Wu
  • Non Executive Director
  • Mr. Yao Fang
  • Non Executive Director
  • Ms. Xiaohui Guan
  • Non Executive Director
  • Mr. Udo Johannes Vetter
  • Independent Director
  • Dr. Jia Ai (Allen) Zhang
  • Non Executive Director
  • Mr. Satyanarayana Murthy Chavali
  • Independent Director
  • Mr. Essaji Goolam Vahanvati
  • Independent Director
  • Ms. Naina Lal Kidwai
  • Independent Director

Gland Pharma Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Gland Pharma Corporate Action

  • Date
  • Purpose
  • Remarks
  • 2022-07-20
  • Quarterly Results
  • 2022-05-19
  • Audited Results
  • 2022-01-21
  • Quarterly Results
  • 2021-10-22
  • Quarterly Results
  • 2021-07-21
  • Quarterly Results

Gland Pharma MF Shareholding

  • Name
  • Amount(cr)
  • ICICI Prudential Balanced Advantage Fund Growth
  • 41742
  • Axis Bluechip Fund Growth
  • 35915
  • Mirae Asset Large Cap Fund Regular Growth
  • 32913
  • Axis Long Term Equity Fund Growth
  • 31361
  • UTI Flexi Cap Fund Regular Plan Growth
  • 25448

About Company

Gland Pharma is the leading company in creating some of the most beneficial injectable products that have significance in multiple therapeutic segments. In addition, the company is responsible for creating an online portfolio that allows users to buy their products online with a doctor's prescription. Right now, the company is manufacturing its products in seven different locations in India and which produce 750 million units with ease. The four major manufacturing facilities of the company have 22 production lines in order to provide finished formulations along with the Active Pharmaceutical Ingredient (API) Facilities as well. All the products that the company manufactures are delivered in the form of liquid vials, syringes that are pre-filled, ampoules, drops, and even bags as well. 

In addition to this, the company is also putting a lot of effort into research for manufacturing and creating a delivery system that could hold complex injectables like peptides, suspensions, and long-lasting injectables. Apart from this, Gland Pharma Ltd is also putting its efforts into research and development of synthesizing some of the most complex molecules for the production of their injectables. Lastly, Gland Pharma Ltd is building the market of niche products in the pharmaceutical industry in India and throughout the world. 
 

Products offered by Gland Pharma Ltd.

  • Anti Malarials
  • Anti-Infectives
  • Anti-Neoplastics
  • Blood Related
  • Cardiac
  • Gastro Intestinal
  • Gynaecological
  • Hormones
  • Neuro / Cns
  • Ophthal / Otologicals
  • Others
  • Pain / Analgesics
  • Respiratory
  • Vitamins / Minerals / Nutrients

 

Gland Pharma Ltd is listed on 2 exchanges, and these are:

 

  • National Stock Exchange of India Ltd.
  • The Stock Exchange, Mumbai


Included in Indices

 

  • NIFTY 50 - No 
  • NIFTY next 50 - YES
  • NIFTY 100 - YES
  • S&P BSE 200 - YES
  • S&P BSE 250 large midcap index- YES
  • S&P BSE finance- NO

 

Other listing information

 

  • Incorporation date - March 20 1978
  • BSE group - A 
  • BSE Code - 543245
  • NSE - GLANDEQ

 

History

 

1978
PVN Raju establishes Gland Pharma to manufacture and market Heparin injection in the domestic market, as well as to provide contract manufacturing services to other pharmaceutical companies.


1994
From a private limited company, it becomes a public limited company.


1996
Becomes the first company to establish a PFS facility in India.

2000
Signs its first Contract Manufacturing agreement for regulated markets

2007
Enters the US market with Ketorolac PFS


2013
Entered European markets with Tirofiban
The Visakhapatnam Oncology Formulations Facility has been approved by the USFDA.


2016
In 2016, the USFDA granted the first approval for a Penems plant in Hyderabad, as well as a Sterile Injectable plant in Pashamylaram, Hyderabad.
First USFDA approval for an API plant in VSEZ and another in Pharmacity, Visakhapatnam.


2017
Fosun Pharma acquired a majority stake in the company.


2018
Enoxaparin injection received US market approval in 2018.
The first ophthalmic product has been approved for sale in the United States.

Gland Pharma FAQs

What is Share Price of Gland Pharma ?

Gland Pharma share price is ₹2364 As on 13 August, 2022 | 03:22

What is the Market Cap of Gland Pharma ?

The Market Cap of Gland Pharma is ₹38939.5 Cr As on 13 August, 2022 | 03:22

What is the P/E ratio of Gland Pharma ?

The P/E ratio of Gland Pharma is 35.7 As on 13 August, 2022 | 03:22

What is the PB ratio of Gland Pharma ?

The PB ratio of Gland Pharma is 5.4 As on 13 August, 2022 | 03:22

Is it a good time to invest in Gland Pharma Limited?

Gland Pharma has an operating revenue of Rs.3,981.54 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 39% is great. Various broking houses and analysts recommend 'BUY' on the stock.

What is the stock price CAGR of Gland Pharma Limited?

The stock price CAGR of Gland Pharma Limited for 1 Year is 66%.

Is Gland Pharma Limited debt-free?

Gland Pharma Limited is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

What is the ROE of Gland Pharma Limited?

The ROE of Gland Pharma Limited is 16% is which good.

Who is the Managing Director of Gland Pharma Limited?

Mr. Srinivas Sadu is the Managing Director & Chief Executive Officer of Gland Pharma Limited.

How to buy shares of Gland Pharma Ltd online?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

What are some of the competitors of Gland Pharma Ltd?

Given below is the list of companies that belong to the same industry or manufacture products of a similar niche as Gland Pharma Ltd. 

  • Cipla 
  • Sun Pharma 
  • Pfizer 
  • Lupin
  • Eris Life 
  • Aarti Drugs 
  • Hester Bio
  • RPG Life 
  • Bafna Pharma 
  • Jb Chemicals 

Q1FY23